Hemolytic transfusion reaction in sickle cell disease (HTRSCD)

Specialty: Hematology

Recommendations:

IVIG may be considered among the options for treatment of serious, life-threatening, delayed hemolytic transfusion reactions in SCD patients.

Dose:

No recommended dose or duration listed; however, expert panel recommends up to 2 g/kg divided over 2 to 5 consecutive days.